TRI seeks to partner entrepreneurial companies and individuals with superior emerging product or technology opportunities, hallmarked by a clear strategic plan and a management team with the capabilities to ensure effective execution. These opportunities should offer the potential for significant value creation through, for example, improved efficiencies in drug discovery and development, identification of new therapeutic targets or the introduction of innovative, new drug candidates.

Sector Focus: Therapeutics
TRI intends to maintain a diverse investment portfolio, but is presently concentrating on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes, and dyslipidemias), cardiovascular disorders and diseases of the central nervous system. TRI does not invest in anti-infective diseases, medical devices, or diagnostics.

Sector Focus: Targets and Technologies
TRI is interested in enabling technologies that enhance drug target discovery and lead identification, increase the efficiency of lead optimization and eliminate redundancies in existing discovery operations. In general, these technologies will be a significant advance over existing systems and processes, and have the potential to provide competitive advantage.

Investor Stake
TRI maintains a flexible approach to all investment opportunities. However, our preference is to hold a minority equity interest as co-investors, where the lead investors would include venture capital firms, private equity funds, angels, or institutional investors.